Combination therapy to treat hepatitis B virus
US6528515B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 2, 1999 |
| Grant date | Mar 4, 2003 |
| Priority date | — |
| Expiry date | Nov 2, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.